Argenx SE is a biotechnology company specializing in antibody-based therapies for severe autoimmune diseases and cancer. Founded in 2008 and headquartered in Amsterdam, Netherlands, it employs the SIMPLE Antibody™ platform to develop differentiated therapeutic antibodies. Argenx’s key product, VYVGART (efgartigimod), is approved for treating generalized myasthenia gravis and is being evaluated for other conditions such as primary immune thrombocytopenia and chronic inflammatory demyelinating polyneuropathy. The company maintains solid financial health, supporting its extensive R&D efforts.